These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7111962)

  • 21. Mechanisms of trimethoprim resistance in enterobacteria isolated in Finland.
    Then RL; Hermann F
    Chemotherapy; 1981; 27(3):192-9. PubMed ID: 7226974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro studies with combinations of sulfamoxole and trimethoprim (co-trifamole).
    Grüneberg RN
    Curr Med Res Opin; 1982; 8(2):128-33. PubMed ID: 7105824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative activity of sulfamethoxazole-trimethoprim (SMZ-TMP) on bacteria responsible for ORL infections].
    Joly B; Sirot D; Cluzel M; Chanal M; Bruneau D
    Pathol Biol (Paris); 1984 Jun; 32(6):689-92. PubMed ID: 6611536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity and interaction of trimethoprim and sulphamethoxazole against Escherichia coli.
    Greenwood D; O'Grady F
    J Clin Pathol; 1976 Feb; 29(2):162-6. PubMed ID: 777036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro additive effect of nitrofurantoin combined with trimethoprim-sulfamethoxazole against Serratia marcescens.
    Traub WH; Fukushima PI
    Chemotherapy; 1979; 25(3):140-6. PubMed ID: 378572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiologic features of urinary infections due to enterobacteriaceae resistant to nalidixic acid and trimethoprim.
    Light RB; Ronald AR; Harding G; Fox L; Buckwold FJ
    Scand J Infect Dis; 1981; 13(3):195-202. PubMed ID: 7313574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations.
    Hu LF; Gao LP; Ye Y; Chen X; Zhou XT; Yang HF; Liiu YY; Mei Q; Li JB
    J Chemother; 2014 Oct; 26(5):282-6. PubMed ID: 24588423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro development of rifampin resistance in clinical isolates of Haemophilus influenzae type b.
    Yogev R; Melick C; Glogowski W
    Antimicrob Agents Chemother; 1982 Mar; 21(3):387-9. PubMed ID: 6980621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.
    Hong DJ; Kim JO; Lee H; Yoon EJ; Jeong SH; Yong D; Lee K
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):184-9. PubMed ID: 27475960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antibiotic synergism against ocular fungal isolates.
    Stern GA
    Am J Ophthalmol; 1978 Sep; 86(3):359-67. PubMed ID: 309728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New therapy from old drugs: synergistic bactericidal activity of sulfadiazine with colistin against colistin-resistant bacteria, including plasmid-mediated colistin-resistant mcr-1 isolates.
    Okdah L; Le Page S; Olaitan AO; Dubourg G; Hadjadj L; Rolain JM
    Int J Antimicrob Agents; 2018 May; 51(5):775-783. PubMed ID: 29421171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
    Dong X; Chen F; Zhang Y; Liu H; Liu Y; Ma L
    J Antibiot (Tokyo); 2014 Sep; 67(9):677-80. PubMed ID: 25095805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brodimoprim synergy against Enterococcus faecalis evaluated in vitro.
    Richards RM; Xing JZ
    J Antimicrob Chemother; 1996 Jul; 38(1):27-37. PubMed ID: 8858454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of ionizing radiation on the antimicrobial activity of the antibiotics sulfamethoxazole and trimethoprim.
    Sági G; Szabacsi K; Szabó L; Homlok R; Kovács K; Mohácsi-Farkas C; Pillai SD; Takács E; Wojnárovits L
    J Environ Sci Health A Tox Hazard Subst Environ Eng; 2018 Jul; 53(8):687-693. PubMed ID: 29485359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of fleroxacin in combination with other antimicrobial agents.
    Neu HC; Chin NX
    Am J Med; 1993 Mar; 94(3A):9S-16S. PubMed ID: 8452190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergism of trimethoprim and ciprofloxacin in vitro against clinical bacterial isolates.
    Huovinen P; Wolfson JS; Hooper DC
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):255-7. PubMed ID: 1597204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of emergence of bacterial resistance by combination of two antibiotics: rifampicin and trimethoprim.
    Grüneberg RN; Emmerson AM
    J Antimicrob Chemother; 1980 May; 6(3):349-56. PubMed ID: 6995419
    [No Abstract]   [Full Text] [Related]  

  • 38. [Susceptibility of gram negative bacteria to TMP-SMX and ofloxacin].
    Unal S; Aydin M; Akin A
    Mikrobiyol Bul; 1988; 22(4):316-21. PubMed ID: 3266971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.
    Werth BJ
    J Antimicrob Chemother; 2017 May; 72(5):1410-1414. PubMed ID: 28158617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trimethoprim-resistant Enterobacteriaceae in urinary tract infection.
    Wong CK; Harding GK; Ronald AR; Hoban S
    Can Med Assoc J; 1975 Jun; 112(13 Spec No):54-8. PubMed ID: 1093652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.